Oncotarget

Research Papers:

Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism

Mariona Jové, Sònia Gatius, Andree Yeramian, Manuel Portero-Otin, Núria Eritja, Maria Santacana, Eva Colas, Maria Ruiz, Reinald Pamplona _ and Xavier Matias-Guiu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:52364-52374. https://doi.org/10.18632/oncotarget.10564

Metrics: PDF 1364 views  |   HTML 2057 views  |   ?  


Abstract

Mariona Jové1,*, Sònia Gatius2,*, Andree Yeramian2, Manuel Portero-Otin1, Núria Eritja2, Maria Santacana2, Eva Colas2, Maria Ruiz2, Reinald Pamplona1, Xavier Matias-Guiu2

1Department of Experimental Medicine, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain

2Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain

*These authors have contributed equally to this work

Correspondence to:

Reinald Pamplona, email: reinald.pamplona@mex.udl.cat

Xavier Matias-Guiu, email: fjmatiasguiu.lleida.ics@gencat.cat

Keywords: endocannabinoid system, metabolomic profile, endometrioid endometrial carcinoma, mass spectrometry, personalized medicine

Received: February 12, 2016    Accepted: June 09, 2016    Published: July 13, 2016

ABSTRACT

Metabolomics, an essential technique in precision medicine, contributes to the molecular fingerprinting of tumours, further helping to understand their pathogenesis. In this work, using a LC-ESI-QTOF-MS/MS platform, we demonstrated the existence of a specific metabolomic signature which could define endometrioid endometrial carcinoma (EEC), arising the endocannabinoid system as a potential pathway involved in EC pathogenesis. Metabolomics could also shed light in the processes involved in myometrial invasion, proposing new targets for possible therapeutic intervention. Consequently, we also described a different metabolomic profile in surface endometrioid carcinoma and myometrial invasive front. We validated pathways disclosed by metabolomics by immunohistochemistry. Specifically, endocannabinoid and purine metabolism could be involved in tumor myometrial invasion.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10564